Back to Search
Start Over
Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) has a positive safety and tolerability profile in an open-label, multicenter, phase 3 study in primary immunodeficiency (PI).
- Source :
- Journal of Allergy & Clinical Immunology; Feb2020 Supplement, Vol. 145, pAB31-AB31, 1p
- Publication Year :
- 2020
Details
- Language :
- English
- ISSN :
- 00916749
- Volume :
- 145
- Database :
- Supplemental Index
- Journal :
- Journal of Allergy & Clinical Immunology
- Publication Type :
- Academic Journal
- Accession number :
- 142005734
- Full Text :
- https://doi.org/10.1016/j.jaci.2019.12.824